Omniox is an IND stage biotechnology company founded based on H-NOX technology developed in Michael Marletta’s laboratory at the University of California, Berkeley. We are developing the breakthrough H-NOX platform technology into first-in-class and best-in-class OMX oxygen delivery vehicles that treat a range of significant unmet medical needs where tissue hypoxia drives disease pathology and worsens patient outcomes. Our in-house team is composed of experienced scientific and biotechnology professionals, and our advisory boards include world-leading experts in the appropriate fields of medicine, science, and business. Omniox has received grants and other funding from the National Cancer Institute, National Institute of Neurological Disorders and Stroke, the Wellcome Trust, and private investors. Omniox adheres to NIH/PHS Financial Conflict of Interest requirements.
To pioneer innovative oxygen-based therapies that restore health to patients.
To solve difficult clinical problems where hypoxia plays a central role. Through rigorous science and world-class partnerships, we are developing our proprietary oxygen-delivery platform to provide meaningful therapeutic benefit to patients.
Co-Founder and CEO
Jonathan Winger is co-inventor of the H-NOX technology from which OMX therapeutics are derived, and has 20+ years of experience with production and study of H-NOX and other proteins. Prior to assuming the role of CEO, he oversaw the design and characterization of candidate OMX therapeutics, directed process and analytical development, and managed the manufacture of clinical material. Prior to Omniox, Jonathan was an American Heart Association Postdoctoral Fellow at the University of California, Berkeley, where he carried out biochemistry and structural biology studies on H-NOX proteins, kinases, and other proteins. He obtained his PhD in Medicinal Chemistry at the University of Michigan, where he used spectroscopy and enzymology to study the role of soluble guanylate cyclase (sGC), an H-NOX-containing protein, in nitric oxide signaling pathways. Insights gained from this work contributed to the conception and founding of Omniox. Jonathan has published numerous research papers and abstracts, co-authored several book chapters, is a PI on several research grants, and is an inventor on multiple patents.
VP Research & Development
Ana Krtolica joined Omniox in 2012, became VP of Research in August 2013, and is currently VP of Research & Development, leading Biology and Translational teams focused on bringing novel OMX oxygen delivery drug candidates to the clinic in oncology and ischemic diseases. Prior to joining Omniox, Ana co-founded StemLifeLine, Inc., an early-stage drug discovery company, serving as their CEO and CSO for 6 years. Prior to industry, Ana worked as a career scientist at Lawrence Berkeley National Laboratory with a joint appointment at the University of California, San Francisco. Ana obtained her PhD in Biochemistry at the University of Rochester Cancer Center. Ana has been Principal Investigator on a number of research grants, authored multiple patent applications, and published more than 30 research papers in peer-reviewed journals, as well as a number of reviews and book chapters.
Senior Director, Controller
Julia Simmons joined Omniox in 2018 and brings more than 25 years of experience in finance and accounting, including approximately 15 years in the biotherapeutics and medical device industries, from large publicly traded companies, such as Genentech, to small, privately-funded startup companies. Julia started her career in public accounting, at Arthur Andersen and KPMG, serving both public and private audit clients in the financial services, health care, and construction industries. After nine years in public accounting, Julia left public accounting as a senior manager to join private industry to serve as the CFO at a community bank. Julia holds a bachelor’s degree in business administration in accounting from Western New England University.